Literature DB >> 31468253

Overuse of intravenous infusions in China: focusing on management platform and cultural problems.

Shuangshuang Zeng1,2, Dong Wang3, Wanli Liu4, Yuanliang Yan1,2, Minwen Zhu1,2, Zhicheng Gong5,6, Shusen Sun7,8,9.   

Abstract

This article reviews the current status of the overuse of intravenous (IV) infusions in China and implications to patient safety, and analyzes factors associated with the overuse. Although many factors contribute to the overuse of IV infusions in China, we focus on the construction of an IV infusion management system and tackling cultural problems as the first step to address issues of IV therapy in this commentary.

Entities:  

Keywords:  China; Cultural problems; Infusion management platform; Intravenous infusions; Overuse; Rational use

Mesh：

Year:  2019        PMID： 31468253     DOI： 10.1007/s11096-019-00898-0

Source DB:  PubMed          Journal:  Int J Clin Pharm


  10 in total

1.  Problems with solutions: drowning in the brine of an inadequate knowledge base.

Authors:  D N Lobo; M G Dube; K R Neal; J Simpson; B J Rowlands; S P Allison
Journal:  Clin Nutr       Date:  2001-04       Impact factor: 7.324

2.  Single-Center Analysis of the Potential Inappropriate Use of Intravenous Medications in Hospitalized Patients in China.

Authors:  Shuangshuang Zeng; Dong Wang; Yuanliang Yan; Minwen Zhu; Wanli Liu; Zhicheng Gong; Ling Wang; Shusen Sun
Journal:  Clin Ther       Date:  2019-06-04       Impact factor: 3.393

3.  Traditional Chinese herbal injection: Current status and future perspectives.

Authors:  Haona Li; Siwang Wang; Zhihua Yue; Xuequn Ren; Jielai Xia
Journal:  Fitoterapia       Date:  2018-07-27       Impact factor: 2.882

Review 4.  Pharmacovigilance in China: development and challenges.

Authors:  Ying Zhao; Tiansheng Wang; Guangyao Li; Shusen Sun
Journal:  Int J Clin Pharm       Date:  2018-07-26

5.  Management of chemotherapy extravasation: ESMO--EONS clinical practice guidelines.

Authors:  J A Pérez Fidalgo; L García Fabregat; A Cervantes; A Margulies; C Vidall; F Roila
Journal:  Eur J Oncol Nurs       Date:  2012-12       Impact factor: 2.398

6.  China should reduce the overuse of intravenous infusion.

Authors:  Sanying Yuan
Journal:  BMJ       Date:  2014-02-04

7.  Serve the people or close the sale? Profit-driven overuse of injections and infusions in China's market-based healthcare system.

Authors:  Lucy Reynolds; Martin McKee
Journal:  Int J Health Plann Manage       Date:  2011 Oct-Dec

8.  Traditional Chinese medicine and drug-induced anaphylaxis: data from the Beijing pharmacovigilance database.

Authors:  Xiaotong Li; Sydney Thai; Wenchao Lu; Shusen Sun; Huilin Tang; Suodi Zhai; Tiansheng Wang
Journal:  Int J Clin Pharm       Date:  2018-07-26

Review 9.  The impact of health information technology on patient safety.

Authors:  Yasser K Alotaibi; Frank Federico
Journal:  Saudi Med J       Date:  2017-12       Impact factor: 1.484

10.  Antibiotic prescribing for upper respiratory infections among children in rural China: a cross-sectional study of outpatient prescriptions.

Authors:  Zhitong Zhang; Yanhong Hu; Guanyang Zou; Mei Lin; Jun Zeng; Simin Deng; Rony Zachariah; John Walley; Joseph D Tucker; Xiaolin Wei
Journal:  Glob Health Action       Date:  2017       Impact factor: 2.640
  10 in total
  3 in total

1.  Recent initiatives to enhance the safety of intravenous medications in Chinese hospitals.

Authors:  Shusen Sun
Journal:  Eur J Hosp Pharm       Date:  2020-08-28

2.  Risk Factors for the Onset of Frozen Shoulder in Middle-Aged and Elderly Subjects Within 1 Year of Discharge From a Hospitalization That Involved Intravenous Infusion: A Prospective Cohort Study.

Authors:  Wenping Cao; Jiangnan Chen; Jianfeng Pu; Yunwu Fan; Ye Cao
Journal:  Front Med (Lausanne)       Date:  2022-06-20

3.  Development and Evaluation of an Intravenous Infusion Sequence Annotation System.

Authors:  Ji Qiu; Tingting Deng; Zhuo Wang; Zhangwei Yang; Ting Liu; Yunjie Liu; Rui Li; Fu Dai
Journal:  Appl Clin Inform       Date:  2021-02-03       Impact factor: 2.342
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.